{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T06:40:02Z","timestamp":1764225602331,"version":"3.46.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immunosuppressive drugs, disease-modifying antirheumatic drugs, as methotrexate, glucocorticoids and biological agents can limit the immune response to vaccines and, in some cases, contraindicate their administration. Non-live vaccines are safe also for immunosuppressed paediatric patients. Seroprotection is maintained in children with rheumatic diseases or autoinflammatory diseases (AID) undergoing vaccinations on immunosuppression, except for those treated with high-dose glucocorticoids and B-cell depleting drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed in a retrospective observational study 107 patients (36 males; 71 females) with rheumatological diseases and AID. Median age was 7\u2009\u00b1\u20094 years. Patients were divided into four groups, based on the principal diagnosis: group 1) included 58 patients with juvenile idiopathic arthritis (JIA); group 2) included 30 patients with monogenic AID; group 3) included 14 patients with other rheumatological diseases (SLE, recurrent uveitis, vasculitis, Beh\u00e7et's disease) and group 4) included 5 patients with MIS-C, Kawasaki disease. We assessed adherence to mandatory vaccinations, as well as seasonal influenza and Coronavirus disease 2019 (COVID-19) vaccinations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The vaccination campaign did not obtain the expected results. All the patients, except for two children, showed a good adherence to mandatory vaccinations. The two unvaccinated children were affected by JIA, they were treated with methotrexate (one) and methotrexate plus adalimumab (the other) and did not undergo vaccination because their parents feared a recurrence of the disease. After an appropriate motivational interview with the parents, both children completed the vaccination schedule required for their age. Among the patients, 14% were vaccinated against both influenza and COVID-19; 32% only against COVID-19 and 15% only against seasonal flu; conversely, 39% were not vaccinated nor against flu or against COVID-19.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>It is necessary to support families in the decision to join the vaccination campaigns, with exhaustive information about the benefits of vaccinations also as promoters of a better quality of life.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2025.1672792","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T06:29:16Z","timestamp":1764224956000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Pediatric rheumatic diseases and vaccinations: a promising alliance"],"prefix":"10.3389","volume":"13","author":[{"given":"Giovanni","family":"Corsello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Gilotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clotilde Genesia","family":"Alizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guglielmo Francesco","family":"Benfratello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Cristina","family":"Maggio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/rheumatology\/keaa240","article-title":"Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis","volume":"59","author":"Tibaldi","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1002\/art.42865","article-title":"Defining criteria for disease activity states in systemic juvenile idiopathic arthritis based on the systemic juvenile arthritis disease activity score","volume":"76","author":"Rosina","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12969-017-0213-x","article-title":"A national cohort study on pediatric beh\u00e7et\u2019s disease: cross-sectional data from an Italian registry","volume":"15","author":"Gallizzi","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"105819","DOI":"10.1016\/j.jbspin.2024.105819","article-title":"Influence of gender on Beh\u00e7et\u2019s disease phenotype and irreversible organ damage: data from the international AIDA network Beh\u00e7et's disease registry","volume":"92","author":"Sota","year":"2024","journal-title":"Joint Bone Spine"},{"key":"B5","doi-asserted-by":"publisher","first-page":"13192","DOI":"10.3390\/ijms241713192","article-title":"\u201cNeuroimmunoendocrinology\u201d in children with rheumatic diseases: how glucocorticoids are the orchestra director","volume":"24","author":"Maggio","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"102763","DOI":"10.1016\/j.autrev.2021.102763","article-title":"Interleukin 1\u03b1: a comprehensive review on the role of IL-1\u03b1 in the pathogenesis and treatment of autoimmune and inflammatory diseases","volume":"20","author":"Cavalli","year":"2021","journal-title":"Autoimmun Rev"},{"key":"B7","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1445-5994.1997.tb00934.x","article-title":"Lymphocytopenia in a hospital population\u2014what does it signify?","volume":"27","author":"Castelino","year":"1997","journal-title":"Aust N Z J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"25215","DOI":"10.1038\/srep25215","article-title":"Corrigendum: effects of systemically administered hydrocortisone on the human immunome","volume":"6","author":"Olnes","year":"2016","journal-title":"Sci Rep"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1182\/blood-2007-11-124156","article-title":"Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors","volume":"112","author":"Sharma","year":"2008","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1096\/fj.201500135","article-title":"Corticosteroid modulation of immunoglobulin expression and B-cell function in COPD","volume":"30","author":"Lee","year":"2016","journal-title":"FASEB J"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1172\/JCI106385","article-title":"The effect of hydrocortisone on immunoglobulin metabolism","volume":"49","author":"Levy","year":"1970","journal-title":"J Clin Invest"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1002\/acr.22628","article-title":"Herpes zoster reactivation in patients with rheumatoid arthritis: analysis of disease characteristics and disease-modifying antirheumatic drugs","volume":"67","author":"Pappas","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1136\/annrheumdis-2022-222574","article-title":"EULAR\/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021","volume":"82","author":"Jansen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/cam4.193","article-title":"Evaluation of fitness levels of children with a diagnosis of acute leukemia and lymphoma after completion of chemotherapy and autologous hematopoietic stem cell transplantation","volume":"3","author":"Bianco","year":"2014","journal-title":"Cancer Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"806","DOI":"10.3390\/ijerph14070806","article-title":"Evaluation of fitness and the balance levels of children with a diagnosis of juvenile idiopathic arthritis: a pilot study","volume":"14","author":"Patti","year":"2017","journal-title":"Int J Environ Res Public Health"},{"key":"B16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13052-019-0766-z","article-title":"FMF is not always \u201cfever\": from clinical presentation to \u201ctreat to target\u201d","volume":"46","author":"Maggio","year":"2020","journal-title":"Ital J Pediatr"},{"key":"B17","doi-asserted-by":"publisher","first-page":"757","DOI":"10.55563\/clinexprheumatol\/7xby7y","article-title":"Clinical features, treatment and outcomes of Italian children with enthesitis-related arthritis and juvenile psoriatic arthritis: a cross-sectional cohort study","volume":"42","author":"Rebollo-Gim\u00e9nez","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"918","DOI":"10.3389\/fphar.2019.00918","article-title":"Anakinra drug retention rate and predictive factors of long-term response in systemic juvenile idiopathic arthritis and adult onset still disease","volume":"10","author":"Sota","year":"2019","journal-title":"Front Pharmacol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1093\/rheumatology\/keab419","article-title":"Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the international AIDA registry","volume":"60","author":"Sota","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s10067-018-4119-x","article-title":"Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study","volume":"37","author":"Sota","year":"2018","journal-title":"Clin Rheumatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1071732","DOI":"10.3389\/fmed.2022.1071732","article-title":"Canakinumab as first-line biological therapy in still\u2019s disease and differences between the systemic and the chronic-articular courses: real-life experience from the international AIDA registry","volume":"9","author":"Vitale","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1093\/rheumatology\/keab619","article-title":"Canakinumab in systemic juvenile idiopathic arthritis: real-world data from a retrospective Italian cohort","volume":"61","author":"De Matteis","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s40261-019-00766-9","article-title":"Early treatment of systemic juvenile idiopathic arthritis with canakinumab and complete remission after 2 years of treatment suspension: case report of an adolescent girl","volume":"39","author":"Maggio","year":"2019","journal-title":"Clin Drug Investig"},{"key":"B24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11739-023-03511-5","article-title":"Correction: clinical and laboratory features associated with macrophage activation syndrome in still\u2019s disease: data from the international AIDA network still\u2019s disease registry","volume":"19","author":"Triggianese","year":"2024","journal-title":"Intern Emerg Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"103265","DOI":"10.1016\/j.jaut.2024.103265","article-title":"The HyperPed-COVID international registry: impact of age of onset, disease presentation and geographical distribution on the final outcome of MIS-C","volume":"147","author":"Caorsi","year":"2024","journal-title":"J Autoimmun"},{"key":"B26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13052-024-01658-1","article-title":"Cardiovascular involvement in children with COVID-19 temporally related multisystem inflammatory syndrome (MIS-C): can cardiac magnetic resonance arrive to the heart of the problem?","volume":"50","author":"Maggio","year":"2024","journal-title":"Ital J Pediatr"},{"key":"B27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13052-023-01416-9","article-title":"Ten-month follow-up of patients with COVID-19 temporally related multi-system inflammatory syndrome in children: the experience of the children hospital of Palermo","volume":"49","author":"Maggio","year":"2023","journal-title":"Ital J Pediatr"},{"key":"B28","doi-asserted-by":"publisher","first-page":"734279","DOI":"10.3389\/fimmu.2021.734279","article-title":"Interleukin-1 inhibitors and vaccination including COVID-19 in inflammatory rheumatic diseases: a nonsystematic review","volume":"12","author":"Atag\u00fcnd\u00fcz","year":"2022","journal-title":"Front Immunol"},{"key":"B29","first-page":"583","article-title":"Influenza A H1N1\/2009 vaccine in juvenile dermatomyositis: reduced immunogenicity in patients under immunosuppressive therapy","volume":"30","author":"Guissa","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/acr.21948","article-title":"High disease activity: an independent factor for reduced immunogenicity of the pandemic influenza A vaccine in patients with juvenile systemic lupus erythematosus","volume":"65","author":"Campos","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3899\/jrheum.110721","article-title":"Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease","volume":"39","author":"Aikawa","year":"2012","journal-title":"J Rheumatol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3109\/03009742.2012.709272","article-title":"Effective seroconversion and safety following the pandemic influenza vaccination (anti-H1N1) in patients with juvenile idiopathic arthritis","volume":"42","author":"Aikawa","year":"2013","journal-title":"Scand J Rheumatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.4161\/hv.7.12.17981","article-title":"Immune response to influenza vaccination in children treated with methotrexate or\/and tumor necrosis factor-alpha inhibitors","volume":"7","author":"Woerner","year":"2011","journal-title":"Hum Vaccin"},{"key":"B34","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1546-0096-11-10","article-title":"Prospective surveillance study of acute respiratory infections, influenza-like illness and seasonal influenza vaccine in a cohort of juvenile idiopathic arthritis patients","volume":"11","author":"Carvalho","year":"2013","journal-title":"Pediatr Rheumatol Online J"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e627","DOI":"10.1016\/S2665-9913(21)00212-5","article-title":"The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study","volume":"3","author":"Mahil","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s10165-012-0595-z","article-title":"Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab","volume":"22","author":"Shinoki","year":"2012","journal-title":"Mod Rheumatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1128\/CVI.00175-10","article-title":"Influenza and meningococcal vaccinations are effective in healthy subjects treated with the interleukin-1 beta-blocking antibody canakinumab: results of an open-label, parallel group, randomized, single-center study","volume":"17","author":"Chioato","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B39","first-page":"436","article-title":"Safety and efficacy of influenza vaccination in a prospective longitudinal study of 31 children with juvenile idiopathic arthritis","volume":"30","author":"Toplak","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13052-016-0306-z","article-title":"Kawasaki disease in sicily: clinical description and markers of disease severity","volume":"42","author":"Maggio","year":"2016","journal-title":"Ital J Pediatr"},{"key":"B41","doi-asserted-by":"publisher","first-page":"4482","DOI":"10.1093\/rheumatology\/keac140","article-title":"Humoral response and safety of BNT162b2 mRNA vaccine in children with rheumatic diseases","volume":"61","author":"Akg\u00fcn","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"B42","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00431-022-04646-x","article-title":"Live-attenuated measles, mumps, and rubella booster vaccine in children diagnosed with rheumatic disease: a single-center study","volume":"182","author":"\u00c7akmak","year":"2023","journal-title":"Eur J Pediatr"},{"key":"B43","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/acr.25045","article-title":"2022 American college of rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases","volume":"75","author":"Bass","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B44","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1080\/00325481.2023.2287988","article-title":"Vaccination coverage of children with rheumatic diseases compared with healthy controls: a retrospective case-control study","volume":"135","author":"Akg\u00fcn","year":"2023","journal-title":"Postgrad Med"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1672792\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T06:29:18Z","timestamp":1764224958000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1672792\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":44,"alternative-id":["10.3389\/fped.2025.1672792"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1672792","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"article-number":"1672792"}}